Literature DB >> 20596051

Pharmacotherapy: Is there a place for leflunomide in the treatment of RA?

Manathip Osiri.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20596051     DOI： 10.1038/nrrheum.2010.76

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  10 in total

1.  Weekly dose of leflunomide for the treatment of refractory rheumatoid arthritis: an open pilot comparative study.

Authors:  Juan Jakez-Ocampo; Yvonne Richaud-Patin; J Abraham Simón; Luis Llorente
Journal:  Joint Bone Spine       Date:  2002-05       Impact factor: 4.929

2.  Induction of antinuclear antibodies in patients with rheumatoid arthritis treated with infliximab and leflunomide.

Authors:  Sarah J Bingham; Maya H Buch; Michael A Kerr; Paul Emery; Anabela Tavares Valadäo Barcelos
Journal:  Arthritis Rheum       Date:  2004-12

3.  Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial.

Authors:  Y P M Goekoop-Ruiterman; J K de Vries-Bouwstra; C F Allaart; D van Zeben; P J S M Kerstens; J M W Hazes; A H Zwinderman; H K Ronday; K H Han; M L Westedt; A H Gerards; J H L M van Groenendael; W F Lems; M V van Krugten; F C Breedveld; B A C Dijkmans
Journal:  Arthritis Rheum       Date:  2005-11

4.  Birth outcomes in women who have taken leflunomide during pregnancy.

Authors:  Christina D Chambers; Diana L Johnson; Luther K Robinson; Stephen R Braddock; Ronghui Xu; Janina Lopez-Jimenez; Nicole Mirrasoul; Elizabeth Salas; Yunjun J Luo; Shelia Jin; Kenneth Lyons Jones
Journal:  Arthritis Rheum       Date:  2010-05

Review 5.  Leflunomide for treating rheumatoid arthritis.

Authors:  M Osiri; B Shea; V Robinson; M Suarez-Almazor; V Strand; P Tugwell; G Wells
Journal:  Cochrane Database Syst Rev       Date:  2003

6.  Comparison of combination therapies in the treatment of rheumatoid arthritis: leflunomide-anti-TNF-alpha versus methotrexate-anti-TNF-alpha.

Authors:  Renato De Stefano; Elena Frati; Fernando Nargi; Caterina Baldi; Luana Menza; Mohammed Hammoud; Mauro Galeazzi
Journal:  Clin Rheumatol       Date:  2010-01-16       Impact factor: 2.980

7.  The effectiveness of leflunomide as a co-therapy of tumour necrosis factor inhibitors in rheumatoid arthritis: a population-based study.

Authors:  A Finckh; S Dehler; C Gabay
Journal:  Ann Rheum Dis       Date:  2008-01-29       Impact factor: 19.103

8.  Comparative effectiveness of tumour necrosis factor alpha inhibitors in combination with either methotrexate or leflunomide.

Authors:  A Strangfeld; F Hierse; J Kekow; U von Hinueber; H-P Tony; R Dockhorn; J Listing; A Zink
Journal:  Ann Rheum Dis       Date:  2009-01-06       Impact factor: 19.103

Review 9.  Benefit-risk assessment of leflunomide: an appraisal of leflunomide in rheumatoid arthritis 10 years after licensing.

Authors:  Nicola Alcorn; Sarah Saunders; Rajan Madhok
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

10.  Efficacy and safety of leflunomide 10 mg versus 20 mg once daily in patients with active rheumatoid arthritis: multinational double-blind, randomized trial.

Authors:  G Poór; V Strand
Journal:  Rheumatology (Oxford)       Date:  2004-03-16       Impact factor: 7.580
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.